A
Aminah Jatoi
Researcher at Mayo Clinic
Publications - 440
Citations - 15796
Aminah Jatoi is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 46, co-authored 404 publications receiving 12708 citations. Previous affiliations of Aminah Jatoi include University of Texas Health Science Center at San Antonio & University of North Carolina at Chapel Hill.
Papers
More filters
Journal ArticleDOI
How Did a Multi-Institutional Trial Show Feasibility of Electronic Data Capture in Older Patients With Cancer? Results From a Multi-Institutional Qualitative Study (Alliance A171902)
Nichole A. Martin,Elizabeth S Harlos,Kathryn D. Cook,Jennifer M O'Connor,Andrew B. Dodge,Emily Guerard,Jacqueline M. Lafky,Aminah Jatoi,Jennifer Le-Rademacher +8 more
TL;DR: In this article, the authors studied how a trial in older patients with cancer (Alliance A171603) was successful in capturing the elasticity of the new technology.
Journal ArticleDOI
Prophylactic doxycycline (doxy) lessens rash from dacomitinib (D) an EGFR inhibitor with no rash or diarrhea improvement from corticosteroids or probiotics.
Mario E. Lacouture,Dorothy M. K. Keefe,Stephen T. Sonis,Nagdeep Giri,Tao Wang,Arlene Reisman,Eric Sbar,Diana Gernhardt,Aminah Jatoi +8 more
TL;DR: A randomized patient (pt) blinded trial that explored prophylactic interventions to minimize select dermatologic adverse events of interest (SDAEI) and diarrhea toxicities associated with D, an irreversible small molecule PanHER.
Journal ArticleDOI
Prescriber adherence to antiemetic guidelines with the new agent trifluridine-tipiracil
Daniel S. Childs,Alison Jacobson,Jessica L Mitchell,Joleen M. Hubbard,Harry H. Yoon,Heidi D. Finnes,Axel Grothey,Aminah Jatoi +7 more
TL;DR: It is hypothesized that patients prescribed a new cancer drug, trifluridine-tipiracil, would be at risk for chemotherapy-induced nausea and vomiting because of poor guideline adherence on the part of health care providers.
Journal ArticleDOI
O-55 The outcome of combined modality therapy for non-small cell lung cancer (NSCLC) in the elderly
Steven E. Schild,Philip J. Stella,Susan Geyer,James A. Bonner,William L. McGinnis,Jeffery Brindle,Aminah Jatoi,James R. Jett +7 more
Journal ArticleDOI
Lenalidomide in solid tumor patients with inflammatory cancer cachexia: A multicenter, randomized, double-blind, proof-of-concept study of fixed dose or CRP-response-guided dose or placebo.
Florian Strasser,R. Oberholzer,David Blum,Markus Joerger,Christoph Driessen,S. deWolf-Linder,Sarah R. Haile,R. von Moos,N. Zerkiebel,Aminah Jatoi,Regina Woelky,K.C.H. Fearon,Thomas Cerny +12 more
TL;DR: The potential of lenalidomide in patients with inflammatory cancer cachexia is explored, with a binary, composite, primary endpoint is number of responders, having increase in hand grip strength and in muscle mass CT-scan L3/4 ≥2% at week 8.